Highlights Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Market Closed - OTC Markets Other stock markets 03:51:10 2024-05-16 pm EDT			5-day change	1st Jan Change
0.695 ^USD	+0.71%		+24.11%	-26.84%

Apr. 24	Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI
Feb. 09	Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	Apr. 24	CI
Regen Biopharma, Inc. Files Provisional Patent Application for Accelerating Hematopoietic Reconstitution After an Insult or Chronic Pathology by Administration of Stem Cell Derived Endothelial Progenitor Cells or Endothelial Cells	Feb. 09	CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2023	Jan. 19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2023	Nov. 20	CI
Regen BioPharma, Inc. Outlines Future Steps in CAR T Program	Nov. 14	CI
Regen BioPharma, Inc Receives Second Phase Confirmatory Data on its Duracar CAR-T Cell Therapy Program	23-10-25	CI
Regen Biopharma, Inc. Expects Second Phase of Confirmatory Study Shortly	23-10-18	CI
Studies on Regen Biopharma, Inc.'s Duracar Indicate Potential Suppression of Autoimmunity, Company Retains Contract Research Organization to Conduct Additional Confirmatory Studies	23-09-19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2023	23-07-25	CI
Regen BioPharma, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2023	23-04-18	CI
Regen BioPharma, Inc. Reports Earnings Results for the First Quarter Ended December 31, 2022	23-01-19	CI
Regen BioPharma, Inc. Reports Earnings Results for the Full Year Ended September 30, 2022	22-11-15	CI
Regen BioPharma, Inc. Develops a Non-Exhaustible CAR-T Cell Therapeutic	22-11-10	CI
Regen BioPharma, Inc. Files Provisional Patent on Car-T Cell Capable of Attracting and Educating Naïve T Cells to Kill Cancer	22-10-05	CI
Regen BioPharma, Inc. Files Patent on Paradigm Shifting RNA/DNA-Based Approach to Cancer Immunotherapy	22-09-20	CI
Regen BioPharma, Inc. Begins Experiments Validating Its Proprietary CAR-T Cell Therapy	22-09-13	CI
Regen Biopharma Develops Novel Means of Using Car-T Cell Immunotherapy to Attack Solid Tumors	22-08-25	CI
Regen BioPharma, Inc. Develops Novel Dedifferentiation Approach for Increasing Efficacy of CAR-T Cells to Treat Solid Tumors	22-08-11	CI
Regen BioPharma, Inc. Files Provisional Patent Application on Second Generation Survivin mRNA Cancer Immunotherapy Vaccine	22-07-26	CI
Regen BioPharma, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2022	22-07-22	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Regen BioPharma, Inc.

Equities

RGBP

US75886M3007

Highlights

Filters